Sage Bionetworks to Model Cancer Pathway Data for AstraZeneca | GenomeWeb

Sage Bionetworks and AstraZeneca have begun a collaboration to apply Sage's pathway modeling technology to provide insight into new cancer therapeutics.

Under the terms of the partnership, announced this week, Sage will contribute its computer modeling methodology and AstraZeneca will provide oncology expertise and data on its proprietary compounds.

Financial terms of the deal were not disclosed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.